Innate Pharma: Phase I Clinical Trial of IPH2102/BMS-986015 in Combination With Ipilimumab Announced

Wed Dec 19, 2012 2:15am EST

* Reuters is not responsible for the content in this press release.

MARSEILLES, FRANCE, Dec 19 (Marketwire) -- 
Innate Pharma SA (the "Company") (EURONEXT PARIS: IPH) (FR0010331421),
the innate immunity company developing first-in-class drugs for cancer
and inflammatory diseases, today announces that a second Phase I
combination trial for IPH2102/BMS-986015 was published on the NIH website
ClinicalTrials.gov: http://www.clinicaltrials.gov/ct2/show/NCT01750580.

    This trial follows the Phase I trial of IPH2102/BMS-986015 in combination
with anti-PD-1 nivolumab (BMS-936558) announced in October and published
on the NIH website ClinicalTrials.gov:
http://www.clinicaltrials.gov/ct2/show/NCT01714739. 

    Marcel Rozencweig, Chief Medical Officer of Innate Pharma, said: "In this
second Phase I trial, IPH2102/BMS-986015 will be tested in a variety of
solid tumors, in combination with ipilimumab, the first approved
immunomodulating antibody." He added: "With the Phase II trial in Acute
Myeloid Leukemia and the Phase I in combination with anti-PD-1 nivolumab
previously announced, the anti-KIR approach is undergoing wide early
clinical testing".

    About the Phase I trial with IPH2102/BMS-986015 in combination with
ipilimumab in solid tumors: 

    The purpose of this Phase I open label study is to determine whether the
combination of IPH2102/BMS-986015 and ipilimumab is safe and provide
preliminary information on the clinical activity of the combination.

    The primary outcome will be safety. Secondary outcomes will include a
preliminary assessment of efficacy, as measured by tumor assessment. The
study will be conducted in two parts -- dose escalation and cohort
expansion -- and is expected to enroll approximately 150 patients. Tumor
types will be restricted to the following advanced (metastatic and/or
unresectable) tumor types: melanoma, non-small cell lung cancer --
squamous and non-squamous histology, and castrate resistant prostate
cancer. 

    About IPH2102/BMS-986015:

    IPH2102/BMS-986015 is a fully human monoclonal antibody blocking
interaction between Killer-cell immunoglobulin-like receptors (KIR) on NK
cells with their ligands. Blocking these receptors facilitates activation
of NK cells and, potentially, destruction of tumor cells by the latter.

    IPH2102/BMS-986015 is licensed to Bristol-Myers Squibb Company (NYSE:
BMY). As part of the agreement between Innate Pharma and Bristol-Myers
Squibb, Bristol-Myers Squibb holds exclusive worldwide rights to develop,
manufacture and commercialize IPH2102/BMS-986015 and related compounds
blocking KIR receptors, for all indications. Under the agreement, Innate
Pharma will conduct the development of IPH2102/BMS-986015 through Phase
II in Acute Myeloid Leukemia ("AML"). 

    IPH2102/ BMS-986015 is currently tested in a randomized, double-blind,
placebo-controlled Phase II trial in elderly patients with AML in a
maintenance setting as well as in two combination Phase I trials in solid
tumors, respectively with ipilimumab and with the anti-PD-1 antibody
nivolumab (BMS-936558).

    About Innate Pharma:

    Innate Pharma S.A. is a biopharmaceutical company developing
first-in-class immunotherapy drugs for cancer and inflammatory diseases. 

    The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate
immunity cells. Its innovative approach has been validated by licence
agreements with two major pharmaceutical companies, Novo Nordisk A/S and
Bristol-Myers Squibb.

    Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate
Pharma is based in Marseilles, France, and had 81 employees as at
September 30, 2012.

    Learn more about Innate Pharma at www.innate-pharma.com.

    Practical Information about Innate Pharma shares:
 ISIN code:
FR0010331421
 Ticker code: IPH

    Disclaimer:

    This press release contains certain forward-looking statements. Although
the company believes its expectations are based on reasonable
assumptions, these forward-looking statements are subject to numerous
risks and uncertainties, which could cause actual results to differ
materially from those anticipated. For a discussion of risks and
uncertainties which could cause the company's actual results, financial
condition, performance or achievements to differ from those contained in
the forward-looking statements, please refer to the Risk Factors
("Facteurs de Risque") section of the Document de Reference prospectus
filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website (
www.innate-pharma.com).

    This press release and the information contained herein do not constitute
an offer to sell or a solicitation of an offer to buy or subscribe to
shares in Innate Pharma in any country.

    121219_IPH_Phase I trial ipilimumab 

http://hugin.info/155662/R/1666158/540716.pdf 

    

For additional information, please contact:

Innate Pharma 
Laure-Helene Mercier 
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87
investors@innate-pharma.com 

ATCG Press
Marielle Bricman
Mob.: +33 (0)6 26 94 18 53
mb@atcg-partners.com 

Copyright 2012, Marketwire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.